PRDX6 and gastroesophageal junction adenocarcinoma: For example, in our previous research, the AUC of autoantibodies against a panel of six TAAs (p53, NYESO-1, PRDX6, MMP-7, Hsp70, and BMI-1) might improve to 0.786 with a sensitivity of 50.0% and a specificity of 90.5% in the diagnosis of early-stage esophagogastric junction adenocarcinoma when compared with the individuals [24].